Search - tctmd.com

Displaying 321 - 340 of 448

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

Shelley Wood

November 07, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

Presentation TCT 2016

Case Presentation: LAA Intervention in the TAVR Patient

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Alexey Protopopov

November 01, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

News Conference News TCT 2016

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Todd Neale

November 01, 2016

News Industry News

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Case #2: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Augusto D. Pichard

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Case #1: A TAVR Complication to Learn From

Presenter: Antonio Colombo, Jeffrey W. Moses, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

TCT 77: Association of Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement With Readmission for Acute Heart Failure: An Analysis From PARTNER 1

Presenter: John M. Lasala, Philippe Pibarot, John Petersen

October 31, 2016

Presentation TCT 2016

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Philip Green

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

Comments and What I Might Have Done Differently

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Jose Armando Mangione

October 30, 2016

Presentation TCT 2016

Case 4: A Patient With Severe Aortic Valve Stenosis and Intermediate Surgical Risk. How Did I Treat It?

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Antonio Enrique Dager

October 30, 2016

Advertisement

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Case Presentation: LAA Intervention in the TAVR Patient

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Five Year Echocardiogram Follow-Up Data Demonstrates Sustained Durability After Transcatheter Aortic Valve Replacement In High-Risk And Inoperable Patients

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Case #2: A TAVR Complication to Learn From

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Case #1: A TAVR Complication to Learn From

TCT 77: Association of Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement With Readmission for Acute Heart Failure: An Analysis From PARTNER 1

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Comments and What I Might Have Done Differently

Case 4: A Patient With Severe Aortic Valve Stenosis and Intermediate Surgical Risk. How Did I Treat It?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content